$125.40
0.34[0.27%]
At close: Apr 17
$125.40
0[0.00%]
After Hours: 5:18PM EDT
Merck & Co
(NYSE:MRK)Merck & Co Stock (NYSE:MRK), Analyst Ratings, Price Targets, Predictions
Merck & Co Inc has a consensus price target of $117.07, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from Berenberg, Cantor Fitzgerald, and Cantor Fitzgerald on April 8, 2024, April 5, 2024, and April 1, 2024. With an average price target of $137.67 between Berenberg, Cantor Fitzgerald, and Cantor Fitzgerald, there's an implied 9.78% upside for Merck & Co Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Berenberg
Cantor Fitzgerald
Truist Securities
Wells Fargo
Societe Generale
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Merck & Co
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/08/2024 | MRK | Buy Now | Merck & Co | $125.40 | 14.04% | Berenberg | Luisa Hector | $140 → $143 | Maintains | Buy | Get Alert |
| 04/05/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Cantor Fitzgerald | Louise Chen | → $135 | Reiterates | Overweight → Overweight | Get Alert |
| 04/01/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Cantor Fitzgerald | Louise Chen | → $135 | Reiterates | Overweight → Overweight | Get Alert |
| 03/28/2024 | MRK | Buy Now | Merck & Co | $125.40 | 13.24% | Truist Securities | Robyn Karnauskas | $139 → $142 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Cantor Fitzgerald | Louise Chen | → $135 | Reiterates | Overweight → Overweight | Get Alert |
| 03/27/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Wells Fargo | Mohit Bansal | $130 → $135 | Maintains | Equal-Weight | Get Alert |
| 03/11/2024 | MRK | Buy Now | Merck & Co | $125.40 | -17.07% | Societe Generale | Justin Smith | → $104 | Downgrade | Hold → Sell | Get Alert |
| 03/11/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Cantor Fitzgerald | Louise Chen | → $135 | Reiterates | Overweight → Overweight | Get Alert |
| 02/29/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Cantor Fitzgerald | Louise Chen | → $135 | Reiterates | Overweight → Overweight | Get Alert |
| 02/14/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Cantor Fitzgerald | Louise Chen | → $135 | Reiterates | Overweight → Overweight | Get Alert |
| 02/05/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Cantor Fitzgerald | Louise Chen | → $135 | Reiterates | Overweight → Overweight | Get Alert |
| 02/02/2024 | MRK | Buy Now | Merck & Co | $125.40 | 10.85% | Truist Securities | Robyn Karnauskas | $122 → $139 | Maintains | Buy | Get Alert |
| 02/02/2024 | MRK | Buy Now | Merck & Co | $125.40 | 18.02% | UBS | Colin Bristow | $135 → $148 | Maintains | Buy | Get Alert |
| 02/02/2024 | MRK | Buy Now | Merck & Co | $125.40 | 3.67% | Wells Fargo | Mohit Bansal | $125 → $130 | Maintains | Equal-Weight | Get Alert |
| 02/02/2024 | MRK | Buy Now | Merck & Co | $125.40 | 15.63% | Barclays | Carter Gould | $135 → $145 | Maintains | Overweight | Get Alert |
| 01/23/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Barclays | Carter Gould | $130 → $135 | Maintains | Overweight | Get Alert |
| 01/09/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Cantor Fitzgerald | Louise Chen | → $135 | Reiterates | Overweight → Overweight | Get Alert |
| 01/04/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | TD Cowen | Steve Scala | $125 → $135 | Upgrade | Market Perform → Outperform | Get Alert |
| 11/29/2023 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Cantor Fitzgerald | Louise Chen | → $135 | Reiterates | Overweight → Overweight | Get Alert |
FAQ
What is the target price for Merck & Co (MRK)?
The latest price target for Merck & Co (NYSE: MRK) was reported by Berenberg on April 8, 2024. The analyst firm set a price target for $143.00 expecting MRK to rise to within 12 months (a possible 14.04% upside). 39 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Merck & Co (MRK)?
The latest analyst rating for Merck & Co (NYSE: MRK) was provided by Berenberg, and Merck & Co maintained their buy rating.
When was the last upgrade for Merck & Co (MRK)?
The last upgrade for Merck & Co Inc happened on January 4, 2024 when TD Cowen raised their price target to $135. TD Cowen previously had a market perform for Merck & Co Inc.
When was the last downgrade for Merck & Co (MRK)?
The last downgrade for Merck & Co Inc happened on March 11, 2024 when Societe Generale changed their price target from N/A to $104 for Merck & Co Inc.
When is the next analyst rating going to be posted or updated for Merck & Co (MRK)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Merck & Co, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Merck & Co was filed on April 8, 2024 so you should expect the next rating to be made available sometime around April 8, 2025.
Is the Analyst Rating Merck & Co (MRK) correct?
While ratings are subjective and will change, the latest Merck & Co (MRK) rating was a maintained with a price target of $140.00 to $143.00. The current price Merck & Co (MRK) is trading at is $125.40, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.